Objectives: This study evaluated the clinical activity and toxicity of combination chemotherapy with irinotecan and oxaliplatin in patients with advanced pancreatic cancer that had progressed despite ≧1 course of a gemcitabine-containing regimen. Methods: Thirty patients with metastatic pancreatic cancer and Karnofsky performance status ≧70 received oxaliplatin 60 mg/m2 on days 1 + 15 and irinotecan 60 mg/m2 on days 1 + 8 + 15 every 4 weeks. Patients were assessed on the basis of clinical benefit response, changes in serum tumour marker CA 19-9, objective tumour response, time to progressive disease (TTP), and survival. Results: Six patients (20%) had clinical benefit response (median duration of 7.2 months). CA 19-9 levels were reduced ≧50% from baseline in 8 patients (26%) and remained stable in 8 patients. CT scans revealed that 3 patients (10%) had a partial response and 7 (23%) had stable disease. Two patients (7%) were down-staged and underwent surgery. Median TTP was 4.1 months, median survival was 5.9 months and the 1-year survival rate was 23.3%. The most serious adverse events were grade 3–4 leukopenia in 2 patients (6%), grade 3 neuropathy in 2 (6%) and grade 3 diarrhoea in 1 (3%). Conclusion: Chemotherapy with irinotecan and oxaliplatin is an active and well-tolerated combination in patients with advanced pre-treated pancreatic cancer.

Keywords:
Pretreated pancreatic cancer, Irinotecan, Oxaliplatin
1.
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer Statistics, 2003.CA. Cancer J Clin 2003;53:5–26
2.
Heinemann V: Present and future treatment of pancreatic cancer. Semin Oncol 2002;29(3, suppl 9):23–31.
3.
Lionetto T, Pugliese V, Bruzzi P, Rosso R: No standard treatment is available for advanced pancreatic cancer. Eur J Cancer 1995;31A:882–887.
4.
Haller DG: Future directions in the treatment of pancreatic cancer. Semin Oncol 2002;29(6, suppl 20):31–39.
5.
Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403–2413.
6.
Klapdor R, Müller C, Seutter R, Bahlo M, Peters W, Fenner C: Improvement of survival by efficacy orientated sequential polychemotherapy of exocrine pancreatic cancer. Anticancer Res 2000;20:5201–5208.
7.
Zeghari-Squalli N, Misset JL, Cvitkovic E, Goldwasser F: Mechanism of the in vitro synergism between SN 38 and oxaliplatin (abstract). Proc Am Assoc Cancer Res 1997;38:A20.
8.
Wasserrmann E, Cuvier Caroline, Lokiec F, Goldwasser F, Kalla S, Méry-Mignard D, Ouldkaci M, Besmaine A, Dupont-André G, Mahjoubi M, Marty M, Misset L, Cvitkovic E: Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1999;17:1751–1759.
9.
Klapdor R, Fenner C: Irinotecan (campto®): Efficacy as third/forth line therapy in advanced pancreatic cancer. Anticancer Res 2000;20:5209–5212.
10.
Gandia D, Abigerges D, Armand JP, Chabot G, Da Costa L, Di Forni M, Mathieu-Boue A, Herait P: CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 1993;11:196–197.
11.
Fishman B, Pasternak S, Wallenstein SL, Houde RW, Holland JC, Foley K: The Memorial Pain Assessment Card: A valid instrument for the evaluation of cancer pain. Cancer 1987;60:1151–1158.
12.
Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF: Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988;6:462–468.
13.
World Health Organization: Handbook for reporting the results of clinical treatment. WHO Offset Publication 48. Geneva, WHO, 1979.
14.
Cantore M, Pederzoli P, Cornalba G, Fiorentini G, Guadagni S, Miserocchi L, Frassoldati A, Ceravolo C, Smerieri F, Muchmore JH: Intra-arterial chemotherapy for unresectable pancreatic cancer. Ann Oncol 2000;11:569–573.
15.
Cvitkovic E, Wasserman E, Goldwasser F, Rougier P, Tigaud JM, Mahjoubi M, Magherini E, Misset JL: Preliminary report on an oxaliplatin/CPT-11 phase I trial in gastrointestinal malignancies: An active combination (abstract). Proc Am Soc Clin Oncol 1997;16:229.
16.
Wagener DJ, Verdonk HE, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis M, Mathieu-Boué A, Verweij J: Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995;6:129–132.
17.
Sakata Y, Shimada Y, Yoshino M, Kambe M, Futatsuki K, Nakao I, Ogawa N, Wakui A, Taguchi T: A late phase II study of CPT-11 in patients with advanced pancreatic cancer. CPT-11 study group on gastrointestinal cancer. Gan to Kagaku Ryoho 1994;21:1039–1046.
18.
Kornmann M, Kafkler H, Butzer U, Beger HG, Link KH: Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Anticancer Res 2000;20:3259–3264.
19.
Kemeny N, Tong W, Stockman J, Blanchette J, Saltz L: Phase I trial of weekly Oxaliplatin and Irinotecan in previously treated patients with metastatic colorectal cancer (abstract 948). Proc Am Soc Clin Oncol 2000;19..
20.
Scheithauer W, Lathan B, Kornek G, Raderer M, Valencak J, Klein G, Hejna M, Brodovic T, Weinlander G, Depisch D: Irinotecan plus oxaliplatin ± G-CSF as second line therapy in patients with advanced 5-FU/leucovorin-refractory colorectal cancer (abstract 658). Ann Oncol 1998;9(suppl 2):172.
21.
Rocha Lima CMS, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR: Irinotecan plus gemcitabine induced both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002;20:1182–1191.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.